Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neuralstem, a biotherapeutics company, has entered into collaboration with the China Medical University & Hospital of Taiwan, to advance development of Neuralstem's human spinal cord neural stem cell therapies.
Subscribe to our email newsletter
The collaboration will focus on amyotrophic lateral sclerosis (ALS) with Shinn-Zong Lin as principle investigator.
Richard Garr, president and CEO of Neuralstem, said: “We are pleased to have established this collaboration in Taiwan. The goal is to qualify our existing cGMP spinal cord cells into a human trial program to treat ALS in Taiwan. We would expect the Taiwan trial to follow the US trial by about six to nine months.
“As we prepare to submit an investigational new drug to treat ALS with our stem cells in the US this fall, we continue to look for strategic relationships in both Europe and Asia that will allow us to move the cells into humans.”